04 November 2024
04 November 2024
The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic kidney disease.
The US District Court upholds the FDA’s approval of Avadel’s Lumryz, dismissing Jazz’s challenge over market exclusivity for its own drug.
The company is preparing to launch a Phase Ib/II study in the US and Japan in the first quarter of 2025.
The new structure, resembling a polymer, protects peptides from degradation and facilitates their entry to cells.
Decentralized and hybrid clinical trials are transforming medical research, offering greater flexibility, improved patient engagement, and faster recruitment.
The NDA was submitted under the FDA's accelerated approval pathway.
Through a partnership, the NCCN is adapting its Harmonized Guidelines for cancer treatment for use in Vietnam.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
